Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.69 |
| ▸ | CA1 | P00915 | 6/20 | 0.69 |
| ▸ | CA4 | P22748 | 4/20 | 0.69 |
| ▸ | CA12 | O43570 | 3/20 | 0.67 |
| ▸ | CA5A | P35218 | 3/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.67 |
| ▸ | CA6 | P23280 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CA3 | P07451 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14317794 | 0.87 | CA2 (0.67) | CA2CA1CA4CA12CA5A | |
| SCHEMBL14065773 | 0.85 | NPC1 (0.60) | CA2CA1CA4CA12CA5A | |
| SCHEMBL32679833 | 0.82 | RAB9A (0.56) | CA2CA1CA4CA12CA5A | |
| SCHEMBL32679834 | 0.82 | RAB9A (0.56) | CA2CA1CA4CA12CA5A | |
| SCHEMBL9459715 | 0.81 | CA2 (1.00) | CA2CA1CA4CA12CA5A | |
| SCHEMBL10473056 | 0.80 | CA2 (0.69) | CA2CA1CA4CA12CA5A | |
| SCHEMBL160105 | 0.80 | CA2 (1.00) | CA2CA1CA4CA12CA5A | |
| SCHEMBL10473137 | 0.80 | CA2 (0.69) | CA2CA1CA4CA12CA5A | |
| SCHEMBL10474766 | 0.80 | CA2 (0.69) | CA2CA1CA4CA12CA5A | |
| SCHEMBL11093599 | 0.80 | CA2 (0.86) | CA2CA1CA4CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468734-A1 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | Siemens Medical Solutions USA, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | of Queen Elizabeth near Dublin | 2012-04-19 | — | — | US | disclosed |
| US-7659312-B2 | Inhibitors of Aquaporin 4, methods and uses thereof | NIIGATA UNIVERSITY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659312-B2 | Inhibitors of Aquaporin 4, methods and uses thereof | NIIGATA UNIVERSITY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | NIIGATA UNIVERSITY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | NIIGATA UNIVERSITY (JP) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094963-A1 | TARGETING PRODRUGS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | PTGS2, SI, PTGS1 | CA2 694/4885CA1 402/4885CA4 1117/4885 |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | AQP4, AQP1, AQP3 | CA2 187/4885CA1 563/4885CA4 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.